Literature DB >> 4029226

[Dimensions of the Hamilton Depression Scale. Factor analysis studies].

W Maier, M Philipp, A Gerken.   

Abstract

The results of factor analysis of HAMD are not unitary. Studying the stability in course and the independence of selection criteria for the population we rated two groups (n = 107, n = 98) of inpatients with HAMD; these groups differ in nosological selection criteria. We furthermore rated one group at different timepoints (before treatment and 3 weeks after). The one-factor-solution is the only stable one and the only one which is independent from selection criteria. In all groups the one-factor-solutions show a high similarity with other published solutions of the German version of HAMD. But there is no way to extract a general factor. Thus the ability of HAMD in judging the severity of depression is doubtful. Ways are discussed to circumvent this problem.

Entities:  

Mesh:

Year:  1985        PMID: 4029226     DOI: 10.1007/bf00386061

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Neurol Sci        ISSN: 0175-758X


  17 in total

1.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

2.  [Psychopathometric procedures: II. Standardized assessment procedures].

Authors:  H J Möller; D von Zerssen
Journal:  Nervenarzt       Date:  1983-01       Impact factor: 1.214

3.  [Methodologic studies of the Hamilton rating scale for depression (author's transl)].

Authors:  U Baumann
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1976-12-30

4.  The instrumental use of rating scales for depression.

Authors:  P Bech
Journal:  Pharmacopsychiatry       Date:  1984-01       Impact factor: 5.788

5.  Research diagnostic criteria: rationale and reliability.

Authors:  R L Spitzer; J Endicott; E Robins
Journal:  Arch Gen Psychiatry       Date:  1978-06

6.  A new depression scale designed to be sensitive to change.

Authors:  S A Montgomery; M Asberg
Journal:  Br J Psychiatry       Date:  1979-04       Impact factor: 9.319

7.  Depression factors in depressed and in heterogeneous in-patient samples.

Authors:  M H Michaux; A Suziedelis; K Garmize; J A Rossi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1969-12       Impact factor: 10.154

8.  Clinical investigations into antidepressive mechanisms. I. Antihistaminic and cholinolytic effects: amitriptyline versus promethazine.

Authors:  H Beckmann; M Schmauss
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1983

9.  The Hamilton depression scale. Evaluation of objectivity using logistic models.

Authors:  P Bech; P Allerup; L F Gram; N Reisby; R Rosenberg; O Jacobsen; A Nagy
Journal:  Acta Psychiatr Scand       Date:  1981-03       Impact factor: 6.392

10.  Reliability of depression and associated clinical symptoms.

Authors:  D V Cicchetti; B A Prusoff
Journal:  Arch Gen Psychiatry       Date:  1983-09
View more
  12 in total

1.  Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.

Authors:  Shinichiro Nakajima; Hiroyoshi Takeuchi; Gagan Fervaha; Eric Plitman; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Yukiko Mihashi; Philip Gerretsen; Gary Remington; Benoit Mulsant; Ariel Graff-Guerrero
Journal:  Schizophr Res       Date:  2014-12-30       Impact factor: 4.939

2.  Adaptation and validation of a structured version of the Hamilton Depression Rating Scale for use by non-clinicians in South Africa (AFFIRM-HDRS).

Authors:  Thandi Davies; Emily C Garman; Crick Lund; Marguerite Schneider
Journal:  J Eval Clin Pract       Date:  2019-12-08       Impact factor: 2.431

Review 3.  Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review.

Authors:  Noelle E Carlozzi; Angela Miciura; Nicholas Migliore; Praveen Dayalu
Journal:  J Huntingtons Dis       Date:  2014

4.  Evaluation of quantitative EEG by classification and regression trees to characterize responders to antidepressant and placebo treatment.

Authors:  M Rabinoff; C M R Kitchen; I A Cook; A F Leuchter
Journal:  Open Med Inform J       Date:  2011-02-11

5.  Measuring depression after spinal cord injury: Development and psychometric characteristics of the SCI-QOL Depression item bank and linkage with PHQ-9.

Authors:  David S Tulsky; Pamela A Kisala; Claire Z Kalpakjian; Charles H Bombardier; Ryan T Pohlig; Allen W Heinemann; Adam Carle; Seung W Choi
Journal:  J Spinal Cord Med       Date:  2015-05       Impact factor: 1.985

6.  Trichotillomania: the impact of treatment history on the outcome of an Internet-based intervention.

Authors:  Steffi Weidt; Annette Beatrix Bruehl; Aba Delsignore; Gwyneth Zai; Alexa Kuenburg; Richard Klaghofer; Michael Rufer
Journal:  Neuropsychiatr Dis Treat       Date:  2017-04-21       Impact factor: 2.570

7.  Effects of hyperthermic baths on depression, sleep and heart rate variability in patients with depressive disorder: a randomized clinical pilot trial.

Authors:  Johannes Naumann; Julian Grebe; Sonja Kaifel; Tomas Weinert; Catharina Sadaghiani; Roman Huber
Journal:  BMC Complement Altern Med       Date:  2017-03-28       Impact factor: 3.659

8.  Inefficient Involvement of Insula in Sensorineural Hearing Loss.

Authors:  Xiao-Min Xu; Yun Jiao; Tian-Yu Tang; Jian Zhang; Richard Salvi; Gao-Jun Teng
Journal:  Front Neurosci       Date:  2019-02-20       Impact factor: 4.677

9.  Treatment response classes in major depressive disorder identified by model-based clustering and validated by clinical prediction models.

Authors:  Riya Paul; Till F M Andlauer; Darina Czamara; David Hoehn; Susanne Lucae; Benno Pütz; Cathryn M Lewis; Rudolf Uher; Bertram Müller-Myhsok; Marcus Ising; Philipp G Sämann
Journal:  Transl Psychiatry       Date:  2019-08-05       Impact factor: 6.222

10.  Subjective ratings of emotive stimuli predict the impact of the COVID-19 quarantine on affective states.

Authors:  Héctor López-Carral; Klaudia Grechuta; Paul F M J Verschure
Journal:  PLoS One       Date:  2020-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.